Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients

Diabetes, Obesity and Metabolism

Volumn 18, Issue 12, 2016, Pages 1217-1225

  Smits, Mark M ^a   Tonneijck, Lennart ^a   Muskiet, Marcel H A ^a   Hoekstra, Trynke ^a,b   Kramer, Mark H H ^a   Diamant, Michaela ^a   Nieuwdorp, Max ^a,c,d   Groen, Albert K ^c,e   Cahen, Djuna L ^f   van Raalte, Daniël H ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY OF GRONINGEN   (Netherlands)

^f ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

bile acids; dipeptidyl peptidase 4; DPP 4; gallbladder emptying; gastric emptying; GLP 1; glucagon like peptide 1

Indexed keywords

BILE ACID; CHENODEOXYCHOLIC ACID; CHOLESTEROL; CHOLIC ACID; DEOXYCHOLIC ACID; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN; METFORMIN; PARACETAMOL; PLACEBO; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; URSODEOXYCHOLIC ACID; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BILE ACID BLOOD LEVEL; BILE ACID SYNTHESIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DIGESTIVE TRACT PARAMETERS; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INHIBITION; DRUG WITHDRAWAL; ECHOGRAPHY; FECES ANALYSIS; FEMALE; GALLBLADDER EMPTYING; GALLBLADDER FASTING VOLUME; GLUCOSE BLOOD LEVEL; HEART EJECTION FRACTION; HUMAN; LIPID DIET; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MIDDLE AGED; NAUSEA; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; POLLAKISURIA; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; AGED; AGONISTS; CHEMISTRY; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; FECES; GALLBLADDER; METABOLISM; ORGAN SIZE; PATHOLOGY;

AGED; BILE ACIDS AND SALTS; BLOOD GLUCOSE; CHENODEOXYCHOLIC ACID; CHOLIC ACID; DEOXYCHOLIC ACID; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FASTING; FECES; FEMALE; GALLBLADDER; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; METFORMIN; MIDDLE AGED; ORGAN SIZE; POSTPRANDIAL PERIOD; SITAGLIPTIN PHOSPHATE; SULFONYLUREA COMPOUNDS; ULTRASONOGRAPHY; URSODEOXYCHOLIC ACID;

EID: 84992157064     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12748     Document Type: Article

References (30)

1. Smits MM, Tonneijck L, Muskiet MHA, et al. Gastrointestinal actions of GLP-1 based therapies: glycaemic control beyond the pancreas. Diabetes Obes Metab. 2016;18(2):178–185.
2. Keller J, Trautmann ME, Haber H, et al. Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept. 2012;179(1-3):77–83.
3. Ben-Shlomo S, Shlomo S, Ben, Zvibel I, et al. Dipeptidyl peptidase 4-deficient rats have improved bile secretory function in high fat diet-induced steatosis. Dig Dis Sci. 2013;58(1):172–178.
4. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
5. Korkmaz H, Araz M, Alkan S, Akarsu E. Liraglutide-related cholelithiasis. Aging Clin Exp Res. 2015;27(5):751–753.
6. Pizzimenti V, Giandalia A, Cucinotta D, et al. Incretin-based therapy and acute cholecystitis: a review of case reports and EudraVigilance spontaneous adverse drug reaction reporting database. J Clin Pharm Ther. 2016;41(2):116–118.
7. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
8. Kuipers F, Bloks VW, Groen AK. Beyond intestinal soap--bile acids in metabolic control. Nat Rev Endocrinol. 2014;10(8):488–498.
9. Smits MM, Tonneijck L, Muskiet MHA, et al. Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes. BMJ Open. 2015;5(11):e009579.
10. Glerup H, Bluhme H, Villadsen GE, et al. Gastric emptying: a comparison of three methods. Scand J Gastroenterol. 2007;42(10):1182–1186.
11. Dodds WJ, Groh WJ, Darweesh RM, et al. Sonographic measurement of gallbladder volume. AJR Am J Roentgenol. 1985;145(5):1009–1011.
12. Sari R, Balci MK, Coban E, Karayalcin U. Sonographic evaluation of gallbladder volume and ejection fraction in obese women without gallstones. J Clin Ultrasound. 2003;31(7):352–357.
13. Bastouly M, Arasaki CH, Ferreira JB, et al. Early changes in postprandial gallbladder emptying in morbidly obese patients undergoing Roux-en-Y gastric bypass: correlation with the occurrence of biliary sludge and gallstones. Obes Surg. 2009;19(1):22–28.
14. Vrieze A, Out C, Fuentes S, et al. Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. J Hepatol. 2014;60(4):824–831.
15. van Meer H, Boehm G, Stellaard F, et al. Prebiotic oligosaccharides and the enterohepatic circulation of bile salts in rats. Am J Physiol Gastrointest Liver Physiol. 2008;294(2):G540–G547.
16. Schaap FG, Trauner M, Jansen PLM. Bile acid receptors as targets for drug development. Nat Rev Gastroenterol Hepatol. 2014;11(1):55–67.
17. Napolitano A, Miller S, Nicholls AW, et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014;9(7):e100778.
18. Stone BG, Gavaler JS, Belle SH, et al. Impairment of gallbladder emptying in diabetes mellitus. Gastroenterology. 1988;95(1):170–176.
19. Smits MM, van Raalte DH, Tonneijck L, et al. GLP-1 based therapies: clinical implications for gastroenterologists. Gut. 2016;65(4):702–711.
20. Nunez DJ, Yao X, Lin J, et al. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin. Diabetes Obes Metab. 2016;18(7):654–662.
21. Carulli N, Loria P, Bertolotti M, et al. Effects of acute changes of bile acid pool composition on biliary lipid secretion. J Clin Invest. 1984;74(2):614–624.
22. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrate therapy. Am J Cardiol. 2007;99(6A):3C–18C.
23. Hodge RJ, Lin J, Vasist Johnson LS, et al. Safety, pharmacokinetics, and pharmacodynamic effects of a selective TGR5 agonist, SB-756050, in type 2 diabetes. Clin Pharmacol Drug Dev. 2013;2(3):213–222.
24. van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes. 2014;38(6):784–793.
25. Jinnouchi H, Sugiyama S, Yoshida A, et al. Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Res. 2015;2015:706416.
26. Pratley RE, Nauck M, Bailey T, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010;375(9724):1447–1456.
27. Gutzwiller J-P, Hruz P, Huber AR, et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion. 2006;73(2-3):142–150.
28. Mekjian HS, Phillips SF, Hofmann AF. Colonic secretion of water and electrolytes induced by bile acids: perfusion studies in man. J Clin Invest. 1971;50(8):1569–1577.
29. Devkota S, Turnbaugh PJ. Cancer: an acidic link. Nature. 2013;499(7456):37–38.
30. McCreight LJ, Bailey CJ, Pearson ER. Metformin and the gastrointestinal tract. Diabetologia. 2016;59(3):426–435.